Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23092955 | 0.76 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL9974183 | 0.74 | CTPS1 (0.40) | ALDH1A1LMNAPOLBMAPTMAPK1 | |
| SCHEMBL1475897 | 0.71 | HPGD (0.42) | ALDH1A1LMNAPOLBMAPTMAPK1 | |
| SCHEMBL2182135 | 0.71 | MAPT (0.52) | ALDH1A1LMNAPOLBMAPTL3MBTL1 | |
| SCHEMBL560732 | 0.69 | DAO (0.52) | ALDH1A1MAPT | |
| SCHEMBL361988 | 0.67 | ALDH1A1 (0.40) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL438824 | 0.67 | CYP17A1 (0.35) | — | |
| SCHEMBL31581039 | 0.64 | KDM4A (0.40) | LMNAL3MBTL1 | |
| SCHEMBL29957364 | 0.62 | MAPK14 (0.31) | TRPV1 | |
| SCHEMBL24323396 | 0.61 | DAO (0.47) | ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | ROCK1, ROCK2, MYLK | ALDH1A1 4286/4885LMNA 2009/4885EGFR 3084/4885 |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ALDH1A1 3009/4885LMNA 2919/4885EGFR 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.